Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA ...
NEW YORK and MAINZ, GERMANY, November 10, 2022— Pfizer Inc. and BioNTech SE today announced a booster dose of their Omicron BA.4/BA. 5- adapted bivalent COVID-19 vaccine has been recommended for ...
Pfizer and BioNTech have submitted a request to the FDA for Emergency Use Authorization of an omicron-adapted COVID-19 booster dose for individuals 12 years of age and older. Pending authorization, ...
Pfizer and BioNTech previously announced that their jointly developed COVID-19 vaccine showed over 90% effectiveness in preventing infection based on initial trial data, although scientists ...
(Reuters) -BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralise the new Omicron variant in a laboratory test, an early signal that booster shots ...
A third shot of the children's dose of Pfizer/BioNTech's Covid-19 vaccine raised Omicron-fighting antibodies by 36 times in kids 5 through 11 years of age, the companies said in a news release ...
Vaccine makers are racing to find out whether current COVID-19 jabs provide adequate protection against omicron and how to adapt them to the strain. Moderna on Friday announced its strategy to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback